



LRRK2 G2019S tg Rat Model

This Parkinson's disease rat model is transgenic for the human LRRK2 G2019S gene. Rats are used heterozygous.


- Increased total LRRK2 levels
- Increased pS935 LRRK2 levels
- Unchanged pS1292 LRRK2 levels
- Phosphorylation status modifiable by LRRK2 inhibitor MLI-2

iPSCs with LRRK2 mutation can be used for *in vitro* analyses


Figure 1:
Time-dependent inhibition of LRRK2 kinase activity upon single oral MLI-2 treatment. LRRK2 G2019S tg rats received a single dose of MLI-2 or vehicle and were sacrificed 2, 8, or 24 hours later. Brain levels of total LRRK2 (A), pS935 LRRK2 (B), and pS1292 LRRK2 (C) were quantified by immunosorbent assay. Mean ± SEM; n = 3-4 per group. Two-way ANOVA with Bonferroni's post hoc test; **p<0.01, ***p<0.001; ns, not significant.

Figure 1

Total LRRK2 Levels



pS935 LRRK2 Levels



pS1292 LRRK2 Levels

